Back to Research Hub
Spyre Therapeutics, Inc.
SYRE
$76.44+4.44 (+6.17%)
Spyre Therapeutics, Inc., a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD).
StreetsValue research for Spyre Therapeutics, Inc. (SYRE)
Members get the full report for Spyre Therapeutics, Inc.: a fair value estimate and valuation analysis, economic moat rating, growth and profitability factor grades, a bull and bear investment thesis, analyst price targets, insider and congressional trading activity, and which super investors own the stock.